Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,019 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expanded ILC2s in human infant intestines promote tissue growth.
Möller KJ, Wegner LHM, Malsy J, Baumdick ME, Borggrewe M, Jordan-Paiz A, Jung JM, Martrus G, Kretschmer P, Sagebiel AF, Schreurs RRCE, Hagen SH, Burmester G, Clauditz TS, Pals ST, Boettcher M, Melling N, Sauter G, Tomuschat C, Königs I, Schumacher U, Altfeld M, Bernink JH, Perez D, Reinshagen K, Bunders MJ. Möller KJ, et al. Among authors: burmester g. Mucosal Immunol. 2023 Aug;16(4):408-421. doi: 10.1016/j.mucimm.2023.04.004. Epub 2023 Apr 29. Mucosal Immunol. 2023. PMID: 37121384 Free article.
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study.
Burmester G, Klimiuk PA, Trefler J, Jaworski J, Kim S, Bae Y, Jeon D, Lee H, Jang J, Hwang C, Lee H, Smolen JS. Burmester G, et al. Expert Rev Clin Immunol. 2025 Jan 13. doi: 10.1080/1744666X.2025.2451215. Online ahead of print. Expert Rev Clin Immunol. 2025. PMID: 39803727
Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study.
Shaharir SS, Nawi AM, Mariamutu TN, Kamaruzaman L, Said MSM, Rajalingham S, Parodis I, Sarkar M, Shinjo SK, Kadam E, Ziade N, Tan CL, Gullemin F, Caballero-Uribe CV, Tan AL, Andreoli L, Parihar J, Yaadav P, Saha S; COVAD Study Group; Gupta L, Agarwal V. Shaharir SS, et al. Int J Rheum Dis. 2025 Jan;28(1):e70043. doi: 10.1111/1756-185X.70043. Int J Rheum Dis. 2025. PMID: 39791506
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, Askling J, Gente K, Bertheussen H, Bitoun S, Bolek EC, Buch MH, Burmester GR, Canhão HM, Chatzidionysiou K, Curtis JR, Danlos FX, Guimarães V, Hetland ML, Iannone F, Kostine M, Kragstrup TW, Kvien TK, Regierer AC, Schulze-Koops H, Sedmak N, Silva-Fernández L, Szekanecz Z, Lauper K, Finckh A, Gottenberg JE. Sebbag E, et al. Among authors: burmester gr. Ann Rheum Dis. 2024 Dec 20:ard-2024-225981. doi: 10.1136/ard-2024-225981. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39739386
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
Sebbag E, Lauper K, Molina-Collada J, Aletaha D, Askling J, Gente K, Bertheussen H, Bitoun S, Bolek EC, Burmester GR, Canhão HM, Chatzidionysiou K, Curtis JR, Danlos FX, Guimarães V, Hetland ML, Iannone F, Kostine M, Kragstrup TW, Kvien TK, Regierer AC, Schulze-Koops H, Silva-Fernández L, Szekanecz Z, Buch MH, Finckh A, Gottenberg JE. Sebbag E, et al. Among authors: burmester gr. Ann Rheum Dis. 2024 Dec 20:ard-2024-225982. doi: 10.1136/ard-2024-225982. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39739385
Improving organisation to improve care: ERN ReCONNET organisational reference model for systemic sclerosis patients' care pathway.
Talarico R, Marinello D, Palla I, Cannizzo S, Galetti I, Farrington S, Aguilera S, Andersen J, Ceccatelli E, Cornet A, Cutillas G, Esteves M, Frank C, Leite C, Niehaus G, Perez Gomez E, Polfliet K, Sandulescu S, Schriemer R, Barsotti S, Bellando-Randone S, Beretta L, Bernardino V, Boleto G, Bombardieri S, Burmester G, Cavazzana I, Codullo V, Cutolo M, Dalm V, Damian L, Della Rossa A, Doria A, Farhat MM, Fonseca JE, Hachulla E, Houssiau F, Grazia Lazzaroni M, Limper M, Lorenzoni V, Montecucco C, Mosca M, Mouthon L, Müeller-Ladner U, Pha M, Ponte C, Spierings J, Sulli A, Taulaigo AV, Ticciati S, Tincani A, Toplak N, Trieste L, van Hagen PM, van Laar J, Vanthuyne M, Vigone B, de Vries-Bouwstra JK, Zen M, Turchetti G, Smith V, Matucci Cerinic M. Talarico R, et al. Among authors: burmester g. J Scleroderma Relat Disord. 2024 Oct 7:23971983241269109. doi: 10.1177/23971983241269109. Online ahead of print. J Scleroderma Relat Disord. 2024. PMID: 39544904 Free PMC article.
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
Baker KF, Spierings J, Brom M, Radstake T, Smith E, Weiss R, Burmester GR; FOREUM Boot Camp Working Group member. Baker KF, et al. Among authors: burmester gr. Ann Rheum Dis. 2024 Nov 12:ard-2024-226772. doi: 10.1136/ard-2024-226772. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39532310 Free article. No abstract available.
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Smolen JS, Trefler J, Racewicz A, Jaworski J, Zielińska A, Krogulec M, Jeka S, Wojciechowski R, Kolossa K, Dudek A, Krajewska-Włodarczyk M, Hrycaj P, Klimiuk PA, Burmester GR, Kim S, Bae Y, Yang G, Jung Y, Hong J, Keystone E. Smolen JS, et al. Among authors: burmester gr. RMD Open. 2024 Oct 18;10(4):e004514. doi: 10.1136/rmdopen-2024-004514. RMD Open. 2024. PMID: 39424404 Free PMC article. Clinical Trial.
1,019 results